None listed
Conditions
Interventions
None listed
Sponsors
Kao Corporation
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Women aged 20-49 who could attend the examination site. 2) Women with normal menstrual cycles i.e., cycles between 25-38 days with variations in cycles within 3 days, and women who can report last 3 menstrual periods. 3) Women who have previously tried to get pregnant. 4) Women who either get pregnant within approximately six months without visiting a gynecologist after wishing to become pregnant or have more than one year of experience in trying to conceive and have experience visiting a gynecologist for fertility treatment. 5) Women with no history of gynecological diseases (such as uterine fibroids, adenomyosis, endometriosis, dysplasia, cervical cancer, etc.). 6) Women who are not currently pregnant. 7) Women who agree to the following measurements: ?Measurement of uterine artery blood flow and endometrial thickness (transabdominal ultrasound) ?Measurement of blood flow of the fingers and toes (laser Doppler) ?Blood pressure measurement ?Blood sampling (related to hormones and metabolomics) ?Collection of vaginal secretions (vaginal discharge) (for analysis of vaginal bacterial flora) 8) Women who can cooperate with the following during the participation cooperation period (1 month) ?Ovulation tests ?Body temperature measurement by applying a temperature patch sensor to the body (groin area) for one month
Exclusion criteria
Exclusion criteria: 1) Women who have had a fever or respiratory symptoms themselves or in their family, or have had close contact with a person infected with the novel coronavirus, within two weeks prior to attending the examination venue. 2)Women with liver, kidney, heart disease, respiratory disorders, endocrine disorders, metabolic disorders (hypertension), neurological disorders, consciousness disorders, or diabetes, as well as those who find it difficult to participate in the study due to other illnesses. 3) Women who have undergone medication treatment or surgery due to severe illness or injury within one month prior to the start of this study and who are deemed unsuitable by the principal investigator or study staff (excluding transient symptoms such as colds or pollen allergies). 4) Women who are unable to maintain a consistent (same) intake of specific health foods, functional foods, and dietary supplements (such as capsule supplements) or exercise habits from one month prior to the start of this study. 5) Women who have participated in other pharmaceutical or food trials within the past month or who are scheduled to participate during this study period. 6) Women who have previously experienced discomfort or worsening health from blood draws. 7) Women with metal allergies or those who have a pacemaker or similar device implanted in their body. 8) Women who are not on day shifts (those who have night rotation work). 9) Women undergoing hormone replacement therapy (HRT) or taking medications that may affect hormones (including pills). 10) Women who are currently pregnant or breastfeeding. 11) Women who have experienced skin abnormalities from applying tape in the past. 12) Women deemed unsuitable for participation in this study by the principal investigator and researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Uterine artery pulsatility index (PI) and resistance index (RI) during the implantation period. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood flow of fingers and toes, blood pressure, and hormone levels in the blood during the implantation period. | — |
Countries
Japan
Contacts
Public ContactMai Tsunoda
Kao Corporation Human Health Care Products Research
Outcome results
None listed